

## Supplementary Information – *BioDrugs*

### Is the Availability of Biosimilar Adalimumab associated with Budget Saving?

#### A Difference-in-Difference Analysis of 14 Countries

Hyunjung Woo<sup>1</sup>, Gyeongseon Shin<sup>1</sup>, Donghwan Lee<sup>2</sup>, Hye-Young Kwon<sup>3\*</sup>, SeungJin Bae<sup>1\*</sup>

<sup>1</sup>College of Pharmacy, Ewha Womans University, Seoul, South Korea

<sup>2</sup>Department of Statistics, Ewha Womans University, Seoul, South Korea

<sup>3</sup>Department of Public Health, Mokwon University, Daejeon, South Korea

#### \*Correspondence:

SeungJin Bae,

College of Pharmacy, Ewha Womans University, Seoul, South Korea

Email: [sjbae@ewha.ac.kr](mailto:sjbae@ewha.ac.kr)

Hye-Young Kwon,

Department of Public Health, Mokwon University, Daejeon, South Korea

Email: [haeyoungkwon0111@gmail.com](mailto:haeyoungkwon0111@gmail.com)

#### Funding

This work was supported by the National Research Foundation (NRF-2021R1F1A10502).

#### Conflicts of interest

All authors have no conflicts of interest to declare.

**Table S1** Quarterly consumption rate of adalimumab 40 mg for all included countries

<b>Classification of countries based on the availability of adalimumab biosimilar as of Q4 2018</b>	<b>Country</b>	<b>Q4 2018<sup>a</sup></b>	<b>Q4 2019<sup>a</sup></b>
Available	Austria	99%	99%
	France	96%	93%
	Germany	98%	99%
	Italy	100%	98%
	Spain	94%	93%
	Sweden	98%	98%
	Total	97%	96%
Not available	Australia	100%	100%
	Brazil	100%	99%
	Canada	100%	100%
	Japan	91%	89%
	Korea	100%	100%
	Singapore	100%	99%
	South Africa	100%	100%
	Taiwan	100%	100%
Total	97%	97%	
Total		97%	96%

<sup>a</sup>The quarterly consumption rate of adalimumab 40 mg was calculated by dividing the sales volume in standard units of adalimumab 40 mg by the total sales volume in standard units, encompassing all adalimumab doses, including 20 mg, 40 mg and 80 mg

**Table S2** Dates corresponding to the first marketing of adalimumab biosimilars for each country

<b>Country</b>	<b>Dates corresponding to the first marketing of adalimumab biosimilars</b>
Austria	
France	
Germany	October 16, 2018 <sup>a</sup>
Italy	
Spain	
Sweden	

<sup>a</sup>This was referenced by Big Molecule Watch (Amgen, Sandoz, Samsung, and Mylan Launch Biosimilars in Europe (UPDATED); <https://www.bigmoleculewatch.com/2018/11/02/amgen-sandoz-samsung-and-mylan-launch-biosimilars-in-europe-updated/>. Accessed November 2, 2018.)